Blanca Fuentes1, George Ntaios2, Jukka Putaala3, Brenda Thomas4, Guillaume Turc5, Exuperio Díez-Tejedor1. 1. 1Department of Neurology and Stroke Center, La Paz University Hospital, Autonoma University of Madrid, IdiPaz Health Research Institute, Madrid, Spain. 2. 2Department of Medicine, University of Thessaly, Larissa, Greece. 3. 3Department of Neurology, Helsinki University Hospital, Helsinki, Finland. 4. Centre for Clinical Brain Sciences (CCBS), University of Edinburgh, Edinburgh, Scotland. 5. Department of Neurology, Sainte-Anne Hospital & INSERM U894, Paris, France.
Abstract
BACKGROUND: Hyperglycaemia is a frequent complication in acute stroke that has been shown to be independently associated with larger infarct size, haematoma growth, poor clinical outcome and mortality. This Guideline Document presents the European Stroke Organisation (ESO) Guidelines for the management of blood glucose levels in patients with acute ischemic or haemorrhagic stroke. METHODS: The working group identified related questions and developed its recommendations based on evidence from randomised controlled trials following the standard operating procedure of the ESO. This Guideline Document was reviewed and approved by the European Stroke Organisation Guidelines Committee and the European Stroke Organisation Executive Committee. RESULTS: We found low-quality evidence from clinical trials in ischemic or haemorrhagic stroke exploring the use of intravenous insulin aimed to achieve a tight glycaemic control with different glucose level targets and several other sources of heterogeneity. None of these trials neither the meta-analysis of them have demonstrated any significant benefit of tight glycaemic control with intravenous insulin in acute ischemic or haemorrhagic stroke patients on functional outcome or in survival and they have shown an increased risk for hypoglycaemia. CONCLUSIONS: We suggest against the routine use of tight glycaemic control with intravenous insulin as a means to improve outcomes. The currently available data about the management of glycaemia in patients with acute stroke are limited and the strengths of the recommendations are therefore weak. Nevertheless, this does not prevent that hyperglycaemia in acute stroke patients could be treated as any other hospitalised patient.
BACKGROUND: Hyperglycaemia is a frequent complication in acute stroke that has been shown to be independently associated with larger infarct size, haematoma growth, poor clinical outcome and mortality. This Guideline Document presents the European Stroke Organisation (ESO) Guidelines for the management of blood glucose levels in patients with acute ischemic or haemorrhagic stroke. METHODS: The working group identified related questions and developed its recommendations based on evidence from randomised controlled trials following the standard operating procedure of the ESO. This Guideline Document was reviewed and approved by the European Stroke Organisation Guidelines Committee and the European Stroke Organisation Executive Committee. RESULTS: We found low-quality evidence from clinical trials in ischemic or haemorrhagic stroke exploring the use of intravenous insulin aimed to achieve a tight glycaemic control with different glucose level targets and several other sources of heterogeneity. None of these trials neither the meta-analysis of them have demonstrated any significant benefit of tight glycaemic control with intravenous insulin in acute ischemic or haemorrhagic stroke patients on functional outcome or in survival and they have shown an increased risk for hypoglycaemia. CONCLUSIONS: We suggest against the routine use of tight glycaemic control with intravenous insulin as a means to improve outcomes. The currently available data about the management of glycaemia in patients with acute stroke are limited and the strengths of the recommendations are therefore weak. Nevertheless, this does not prevent that hyperglycaemia in acute stroke patients could be treated as any other hospitalised patient.
Entities:
Keywords:
Acute stroke; European Stroke Organisation; GRADE; guidelines; hyperglycaemia
Authors: Greet Van den Berghe; Alexander Wilmer; Greet Hermans; Wouter Meersseman; Pieter J Wouters; Ilse Milants; Eric Van Wijngaerden; Herman Bobbaers; Roger Bouillon Journal: N Engl J Med Date: 2006-02-02 Impact factor: 91.245
Authors: José Alvarez-Sabín; Carlos A Molina; Joan Montaner; Juan F Arenillas; Rafael Huertas; Marc Ribo; Agusti Codina; Manuel Quintana Journal: Stroke Date: 2003-04-03 Impact factor: 7.914
Authors: Tracey A Baird; Mark W Parsons; Thanh Phan; Thanh Phanh; Ken S Butcher; Patricia M Desmond; Brian M Tress; Peter G Colman; Brian R Chambers; Stephen M Davis Journal: Stroke Date: 2003-07-31 Impact factor: 7.914
Authors: Mark W Parsons; P Alan Barber; Patricia M Desmond; Tracey A Baird; David G Darby; Graham Byrnes; Brian M Tress; Stephen M Davis Journal: Ann Neurol Date: 2002-07 Impact factor: 10.422
Authors: Eivind Berge; William Whiteley; Heinrich Audebert; Gian Marco De Marchis; Ana Catarina Fonseca; Chiara Padiglioni; Natalia Pérez de la Ossa; Daniel Strbian; Georgios Tsivgoulis; Guillaume Turc Journal: Eur Stroke J Date: 2021-02-19
Authors: Gregory Y H Lip; Deirdre A Lane; Radosław Lenarczyk; Giuseppe Boriani; Wolfram Doehner; Laura A Benjamin; Marc Fisher; Deborah Lowe; Ralph L Sacco; Renate Schnabel; Caroline Watkins; George Ntaios; Tatjana Potpara Journal: Eur Heart J Date: 2022-07-07 Impact factor: 35.855